As Canadians anticipate a federal election in a few months’ time, how we pay for drugs and how much they cost is bound to be one of the most pressing issues.
With the recent interim report of the government’s panel on pharmacare and the budget announcement of a new Canadian Drug Agency, there are plenty of questions about how best to ensure affordable and comprehensive coverage for Canadians. To begin to answer these questions, the Macdonald-Laurier Institute assembled a top-level panel of experts with a wide range of perspectives on the issue, from noted physicians to prominent advocates, for a panel discussion.
Some photos from the event are available below. A full gallery may be viewed here.
- Sean Speer, MLI Munk Senior Fellow
- Shawn Whatley, MLI Senior Fellow, former president of the Ontario Medical Association
- Durhane Wong-Reiger, President and CEO of the Canadian Association for Rare Disorders
- Matthew Brougham, Senior Global Consultant, Brougham Consulting & Certara, Evidence & Access, former chief executive of the New Zealand Pharmaceutical Management Agency
- Judith Glennie, President, JL Glennie Consulting Inc., former official in the Canadian and Ontario health ministries